VERTEX PHARMACEUTICALS INC / MA Equity Securities, FV-NI, Unrealized Gain
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Equity Securities, FV-NI, Unrealized Gain of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGain · last filed 2026-08-04
- VERTEX PHARMACEUTICALS INC / MA equity securities, fv-ni, unrealized gain for the quarter ending 2026-06-30 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA equity securities, fv-ni, unrealized gain for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA equity securities, fv-ni, unrealized gain for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA equity securities, fv-ni, unrealized gain for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA equity securities, fv-ni, unrealized gain for fiscal 2024 was $3.00M.
- VERTEX PHARMACEUTICALS INC / MA equity securities, fv-ni, unrealized gain for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA equity securities, fv-ni, unrealized gain for fiscal 2022 was $30.90M, a 81.51% decline from fiscal 2021.
- VERTEX PHARMACEUTICALS INC / MA equity securities, fv-ni, unrealized gain for fiscal 2021 was $167.10M, a 15.72% increase from fiscal 2020.
| Period end | Equity Securities, FV-NI, Unrealized Gain 3 month | Equity Securities, FV-NI, Unrealized Gain 3 month as first filed | Equity Securities, FV-NI, Unrealized Gain 6 month | Equity Securities, FV-NI, Unrealized Gain 6 month as first filed | Equity Securities, FV-NI, Unrealized Gain 9 month | Equity Securities, FV-NI, Unrealized Gain 12 month | Equity Securities, FV-NI, Unrealized Gain 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $0.00 10-Q · filed 2026-08-04 | $0.00 derived: sum of 3 quarters · filed 2026-08-04 | $0.00 derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-05 | $0.00 derived: sum of 2 quarters · filed 2026-08-04 | $0.00 derived: sum of 3 quarters · filed 2026-08-04 | -$3.00M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-12-31 | $0.00 derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-04 | $0.00 derived: sum of 2 quarters · filed 2026-08-04 | -$3.00M derived: sum of 3 quarters · filed 2026-08-04 | $0.00 10-Q · filed 2026-08-04 | |||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$3.00M derived: sum of 2 quarters · filed 2025-11-04 | $0.00 10-Q · filed 2025-11-04 | $2.10M derived: sum of 4 quarters · filed 2026-02-13 | |||
| 2025-06-30 | -$3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $0.00 10-Q · filed 2025-08-05 | $2.10M derived: sum of 3 quarters · filed 2026-02-13 | $3.00M derived: sum of 4 quarters · filed 2026-02-13 | |||
| 2025-03-31 | $3.00M 10-Q · filed 2025-08-05 | $0.00 10-Q · filed 2025-05-06 | $5.10M derived: sum of 2 quarters · filed 2026-02-13 | $6.00M derived: sum of 3 quarters · filed 2026-02-13 | $6.00M derived: sum of 4 quarters · filed 2026-02-13 | ||
| 2024-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $3.00M derived: sum of 2 quarters · filed 2026-02-13 | $3.00M derived: sum of 3 quarters · filed 2026-02-13 | $3.00M 10-K · filed 2026-02-13 | |||
| 2024-09-30 | $900.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $900.00K derived: sum of 2 quarters · filed 2024-11-05 | $900.00K 10-Q · filed 2024-11-05 | $400.00K derived: sum of 4 quarters · filed 2025-02-13 | |||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $0.00 10-Q · filed 2024-08-02 | -$500.00K derived: sum of 3 quarters · filed 2025-02-13 | $0.00 derived: sum of 4 quarters · filed 2025-02-13 | |||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-07 | -$500.00K derived: sum of 2 quarters · filed 2025-02-13 | $0.00 derived: sum of 3 quarters · filed 2025-02-13 | -$47.40M derived: sum of 4 quarters · filed 2025-02-13 | |||
| 2023-12-31 | -$500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $0.00 derived: sum of 2 quarters · filed 2025-02-13 | -$47.40M derived: sum of 3 quarters · filed 2025-02-13 | $0.00 10-K · filed 2025-02-13 | |||
| 2023-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$46.90M derived: sum of 2 quarters · filed 2023-11-07 | $500.00K 10-Q · filed 2023-11-07 | $2.20M derived: sum of 4 quarters · filed 2024-02-15 | |||
| 2023-06-30 | -$47.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $0.00 10-Q · filed 2023-08-02 | $1.70M derived: sum of 3 quarters · filed 2024-02-15 | $18.60M derived: sum of 4 quarters · filed 2024-02-15 | |||
| 2023-03-31 | $47.40M 10-Q · filed 2023-05-02 | $49.10M derived: sum of 2 quarters · filed 2024-02-15 | $66.00M derived: sum of 3 quarters · filed 2024-02-15 | $47.40M derived: sum of 4 quarters · filed 2024-02-15 | |||
| 2022-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $18.60M derived: sum of 2 quarters · filed 2024-02-15 | $0.00 derived: sum of 3 quarters · filed 2024-02-15 | $30.90M 10-K · filed 2024-02-15 | |||
| 2022-09-30 | $16.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | -$1.70M derived: sum of 2 quarters · filed 2022-10-28 | $29.20M 10-Q · filed 2022-10-28 | $46.04M derived: sum of 4 quarters · filed 2023-05-02 | |||
| 2022-06-30 | -$18.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $12.30M 10-Q · filed 2022-08-05 | $29.14M derived: sum of 3 quarters · filed 2023-05-02 | $12.30M derived: sum of 4 quarters · filed 2023-05-02 | |||
| 2022-03-31 | $30.90M 10-Q · filed 2023-05-02 | $92.20M 10-Q · filed 2022-05-06 | $47.74M derived: sum of 2 quarters · filed 2023-05-02 | $30.90M derived: sum of 3 quarters · filed 2023-05-02 | $105.94M derived: sum of 4 quarters · filed 2023-05-02 | ||
| 2021-12-31 | $16.84M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | $0.00 derived: sum of 2 quarters · filed 2023-02-10 | $75.04M derived: sum of 3 quarters · filed 2023-02-10 | $167.10M 10-K · filed 2023-02-10 | |||
| 2021-09-30 | -$16.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $58.20M derived: sum of 2 quarters · filed 2022-05-06 | $150.26M 10-Q · filed 2021-11-03 | $85.44M derived: sum of 4 quarters · filed 2022-05-06 | |||
| 2021-06-30 | $75.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-06 | $167.10M 10-Q · filed 2022-05-06 | $102.67M 10-Q · filed 2021-07-30 | $102.28M derived: sum of 3 quarters · filed 2022-05-06 | $159.23M derived: sum of 4 quarters · filed 2022-05-06 | ||
| 2021-03-31 | $92.06M 10-Q · filed 2021-04-30 | $27.24M derived: sum of 2 quarters · filed 2022-02-09 | $84.19M derived: sum of 3 quarters · filed 2022-02-09 | $158.38M derived: sum of 4 quarters · filed 2022-02-09 | |||
| 2020-12-31 | -$64.82M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | -$7.87M derived: sum of 2 quarters · filed 2022-02-09 | $66.32M derived: sum of 3 quarters · filed 2022-02-09 | $144.40M 10-K · filed 2022-02-09 | $144.35M 10-K · filed 2021-02-11 | ||
| 2020-09-30 | $56.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $131.14M derived: sum of 2 quarters · filed 2020-10-30 | $209.22M 10-Q · filed 2020-10-30 | ||||
| 2020-06-30 | $74.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $152.27M 10-Q · filed 2020-07-31 | |||||
| 2020-03-31 | $78.08M 10-Q · filed 2020-05-01 | ||||||
| 2019-12-31 | $168.25M 10-K · filed 2021-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |